

CLINICAL STUDY

Decreased circulatory microRNA-4478 as a specific biomarker for diagnosing non-ST-segment elevation myocardial infarction (NSTEMI) and its association with soluble leptin receptor

Gholikhani-Darbroud R¹, Khaki-Khatibi F², Mansouri F³, Hajahmadipoorrafsanjani M⁴, Ghojazadeh M⁵

Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
fatemehkhakikhatibi@yahoo.com

ABSTRACT

OBJECTIVE: This study aimed to assess the usefulness of circulatory microRNA-4478 (miR-4478) and soluble leptin receptor (sLEPR) in prognosis and diagnosis of non-ST-segment elevation myocardial infarction (NSTEMI) and to introduce miR-4478 as a new biomarker for NSTEMI disease. This study aimed also to examine correlation between miR-4478 and soluble leptin receptor and effects of miR-4478 on leptin receptor concentration. **BACKGROUND:** MicroRNAs could be used as predictive biomarkers for diseases.

METHODS: We collected sera of 80 angiographically confirmed NSTEMI patients and 80 healthy individuals and performed RNA extraction, cDNA synthesis, measurement of microRNAs, sLEPR and other chemistries. Statistical analyses were done using excel, XLSAT, and SPSS. Quality control analysis was done triplicated for 7 serial dilution of stock cDNA solution.

RESULTS: The patients with NSTEMI had higher serum levels of miR-4478, sLEPR, cTnI, CKMB, Urea, creatinine, glucose, cholesterol, TG, and ALP but lower levels of ALT compared with the normal healthy individuals. We detected decrease in expression of miR-4478 ($2^{-\Delta\Delta Cq} = 0.161 \pm 0.211$) along with increase in sLEPR levels ($F = 3.645$, $p < 0.001$) in the NSTEMI group compared with normal individuals. Pearson's correlation tests indicated positive correlation of miR-4478 and sLEPR ($p < 0.001$, $R^2 = 0.698$). There was sensitivity and specificity of 87.5% and 98.8% for miR-4478 and 92.5% and 87.5% for sLEPR.

CONCLUSION: Circulatory miR-4478 and sLEPR may be used as predictors of NSTEMI. miR-4478 may also be used as a new biomarker for NSTEMI disease (Tab. 3, Fig. 6, Ref. 30). Text in PDF www.elis.sk.

KEY WORDS: microRNA-4478, Leptin receptor, non-ST-segment elevation myocardial infarction, biomarker.

Introduction

Cardiovascular disease (CVD), known as disorder of heart or blood vessels, has various types, depending on its mechanism of action and impact location. CVDs are classified to various cardiac implications and include: coronary artery diseases (CAD), stroke,

heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis (1).

CVDs are the leading cause of global death. In 2008, 30 % of global death was attributed to cardiovascular diseases (2). A 2013 study in Iran showed a high incidence and mortality of CVD (331/100000 in men and 203/100000 in women) (3). CADs are responsible for about 12.2 % of worldwide deaths in high- and middle-income countries (4).

Myocardial infarction (MI; commonly known as heart attack) and angina are presentations of CAD (also known as coronary heart disease (CHD) and ischemic heart disease (IHD)), but MI is more common. Risk factors for CADs include high blood pressure, lack of exercise, diabetes, smoking, obesity, high LDL/HDL among others (5, 6). A number of tests are used to diagnosis CADs, including electrocardiography (ECG), coronary angiography, and some blood tests like cardiac troponin I and T, and less often creatine kinase MB (CK-MB) (7). Increase or not-increase in ST segment on ECG (along with the presence of other signs and symptoms of MI) is the main criterion to classify MI to ST

¹Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, ²Drug Applied Research Center and Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, ³Cellular and Molecular Research Center and Department of Genetics and Immunology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran, ⁴Cardiology Department, Seyedoshohada Cardiovascular Medical Hospital, Urmia University of Medical Sciences, Urmia, Iran, and ⁵Iranian Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Address for correspondence: F. Khaki-Khatibi, Drug Applied Research Center and Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Phone: +984133364666, Fax: +984133364666

Acknowledgement: This work was supported by the research Grant IR.TBZMED.REC.1395.43 of Tabriz University of Medical Sciences for final thesis of Ph.D students.

elevation MI (STEMI) and non-ST elevation MI (NSTEMI), respectively (8). Although a recent classification is presented, STEMI and NSTEMI terms are more accepted and used by health organizations and cardiologists (9).

In contrast to STEMI where the artery is almost totally occluded by clots rich in fibrin and cholesterol that obligates immediate management, the infarct-related artery is partially occluded in NSTEMI. Quick and straightaway diagnosis is important and lifesaving by initiating appropriate therapy to control development of MI and reduce the mortality rate (10).

Leptin receptor (LEPR, OB-R) is a member of cytokine receptor family present in hypothalamic neurons that with the physiologic function of controlling hunger and energy use by binding a fat cell-specific hormone leptin (11). The soluble form of it (sLEPR, sOB-R) that results from cleavage of the extracellular domain of the transmembraneous leptin receptor, has 839 amino acids and may be detected in the circulatory system (12). Circulatory LEPR has two distinctly separate N-glycosylated isoforms and may be present in dimeric or oligomerized states (13). By binding to it in ratio of 1: 1, sLEPR modulates leptin action (14).

Increase in the circulatory leptin receptor and its ligand have been demonstrated in chronic heart failure (15).

Recently along with advances in molecular medicine, nucleotide-based biomarkers for the diagnosis or prognosis of diseases have attracted significant attention. MicroRNAs (miRNAs) are endogenous, single stranded, non-coding RNA particles of 19–25 nucleotides long, encoded by a specific transcription and splicing mechanisms present in both nucleus and cytosol (16). MiRNAs play their critical roles in silencing of specific mRNAs by binding to the 3'-untranslated region (3' UTR) of target mRNA and inhibiting their translation or inducing their degradation (17). MiRNAs are involved in several biochemical processes in the cell, including proliferation, differentiation, development, migration, and apoptosis (18). MiRNAs are excreted to body fluids bounded to specific proteins that give them enough stability to be detected. Various conditions, especially diseases cause excretion of miRNAs from tissues to the body fluids, so variations in their body-fluid levels may be a representation of their variation in the tissue. So miRNAs (specially tissue specific ones) may be used as biomarkers for various diseases, including cardiovascular diseases, and their increase or decrease in tissue or body fluids (including serum) may be used as useful prognostic factors for disease. Some muscle-specific microRNA (called myomiRs or miRs) that would change in tissue-specific disorders, including heart diseases are: miR-1, miR-133a, miR-206, miR-208a, miR-208b, miR-499, and miR-486 (19).

Micro RNA 4478 (miR-4478, Chromosomal location: 9q33.2) has the highest target score (=90) for LEPR (20), so it could be easily deduced that variation in miR-4478 (reflected by changes in its serum level) may affect serum LEPR concentration.

The objectives of this study were evaluating circulatory miR-4478 and sLEPR differentiation between NSTEMI patients and healthy control subjects, calculating the effects of changes in miR-4478 on LEPR level, and investigating the role of miR-4478 as a marker for predicting NSTEMI.

Materials and methods

Ethics statement

The study was approved by the Ethic Committee of Medicine faculty of Tabriz University of Medical Sciences. Blood collection procedures from patients and control groups complied completely with relevant rules of Seyedoshohada Cardiovascular Medical Hospital of Urmia University of Medical Sciences. Before participating in the study, a written informed consent was obtained from each patient and healthy individual that was enrolled in the current study.

Study population

80 hospitalized patients (40 males (50 %) and 40 females (50 %) with age range of 35–80 suffering from NSTEMI with their disease diagnosed by the cardiologists of Seyedoshohada Cardiovascular Medical Hospital were included in the patient group during May 2016 and October 2016. 80 individuals with equal age and sex range referred to the hospital that had normal angiographic and electrocardiographic results were enrolled as control group during the same time period. Patients with a history of malignant disease, liver failure, renal failure, previous history of cardiomyopathy, bleeding disorders and irradiation therapy were excluded from the study. The study was conducted in accordance with WMA Declaration of Helsinki – Ethical Principles for Medical Research and guidelines of the ethics committee of Tabriz University of Medical sciences and Seyedoshohada Cardiovascular Medical Hospital of Urmia, Iran.

Sample collection and storage

Blood samples were collected in mediplex clot-activator containing tubes (Sunphoria Co. Ltd., Taiwan) and left for 10 minutes to complete coagulation and then sera were separated by centrifugation at 10000 rpm for 7 minutes, and transferred to RNase/DNase-free tubes and stored frozen at –80 °C (snijders scientific, The Netherlands) until analysis.

RNA isolation and preparation

Large and small (including micro-) RNAs in serum was isolated in separate tubes using Hybrid-R miRNA Purification Kit (Geneall, Seoul, South Korea) according to instructions of the manufacturer. The procedure includes inactivation of nucleases by RiboEx Buffer (containing phenol and guanidium salt), followed by adding chloroform to push RNAs to aqueous phase (DNA particles remain in interphase and proteins remain in organic phase). Ethanol was added to aqueous phase and large and small RNAs separated, respectively, by type W and type B columns. At last, RNAs were excluded from mentioned columns by RNase/DNase-free water and kept frozen at –80 °C.

Quantification of miR-4478

Total RNA had been polyadenylated and reverse transcribed to make cDNA using the NG dART RT kit (EURx Ltd., Gdansk, Poland) following the manufacturer instructions. As brief, 0.5 µg of the DNase-treated total RNA as template was mixed with 1 µl NG dART RT mix, 1 µl Oligo (dT)₂₀ primed primer, 4 µl of 5× NG

cDNA buffer, and reached to final volume of 20 µl by RNase-free water. The mixture was transferred to preheated thermal cyclor and incubated at 50 °C for 50 minutes to complete the reaction and at 85 °C for 5 minutes to stop it. The obtained cDNA (2.5 µl of a 1/100 dilution) was then amplified with real-time PCR using MIC qPCR Cyclor (biomolecular systems, Australia). Human mature miR-4478 has 17 nucleotides with this sequence: 3'-GAGGCUGAGCUGAGGAG-5'. Primer sets for miR-4478 (hsa-miR-4478 LNA™ PCR primer set, Product no. 2108950), housekeeping internal control, and master mix were shipped from Exiqon (Vedbaek, Denmark). Considering Exiqon recommendations, we used microRNA-423-5p (hsa-miR-423-5pLNA™ PCR primer set, Product no. 205624) as the endogenous housekeeping internal control and ExiLENT SYBR® Green master mix (Product no. 203403) as the master mix.

PCR reactions were conducted at 95 °C for 15 minutes, followed by 40 cycles of 60.5 °C for 20 seconds, and 72 °C for 20 seconds. A melting curve analysis was settled to confirm that there is only one specific peak for miR-4478 and to validate the specificity of PCR product according to the MIQE guidelines (21). The quantification cycle (Cq) values were calculated for each of these: Gene being Tested Experimental (TE.Cq), Gene being Tested Control (TC.Cq), Housekeeping gene Experimental (HE.Cq), and Housekeeping gene Control (HC.Cq). “TE.Cq - HE.Cq” was measured as “ $\Delta Cq.E$ ” and “TC.Cq - HC.Cq” as “ $\Delta Cq.C$ ”. “ $2^{-\Delta Cq.E}$ ” and “ $2^{-\Delta Cq.C}$ ” values were also calculated to better comparison. No enzyme control and no template control (NTC) were included among with case and control samples as the negative controls to discover any potential DNA and/or water/ master mix contamination, respectively. All qRT-PCR reactions (samples, controls, and negative controls) were performed in triplicate and means of them were used as Cq values for each.

Detection of soluble leptin receptor

We used an Enzyme Linked Immunosorbent Assay kit (ELISA) (Zellbio, Germany; Cat. No. ZB-10304-H9648) and followed kit instructions to measure the sLEPR level in NSTEMI patients and healthy control subjects.

Measurement of other circulating substances

Other circulating chemistries were measured by an autoanalyzer system (Autolab, BT 3500, Auto analyzer Medical System, Rome, Italy) and chemiluminescent analyzer (Architect i1000 SR, Abbott, USA) using commercial kits (Pars Azmoon, Tehran, Iran) in the clinical laboratory of Seyedoshohada Cardiovascular Medical Hospital.

Statistical analysis

Analysis of relative gene expression data was done using the $2^{-\Delta\Delta Cq}$ method (21–24). LinReg PCR method (25, 26) in program software was chosen to determine the reaction effectiveness for each primer pair. Microsoft Excel version 2013 (Microsoft Corp., Redmond, WA, USA), XLSTAT Version 2016.02.28451 (Addinsoft, Paris, France) and SPSS version 20 (SPSS Inc., Chicago, IL, USA) softwares were applied to statistical analysis and generation

Tab. 1. Clinical characteristics of patient and control groups.

Characteristics	NSTEMI Patients (n=80)	Healthy Controls (n=80)	Two-tailed p value (t-Test)
Age (years)	62.40±9.86	59.61±10.83	0.091
Male/Female	40/40	40/40	1
Body mass index (kg/m ²)	25.12±4.57	24.89±4.24	0.460
cTnI (ng/l)	18.90±48.68	0.13±0.11	0.001
CKMB (IU/l)	32.87±22.53	17.92±6.21	< 0.001
Urea (mg/dl)	37.47±14.70	28.56±7.12	< 0.001
Creatinine (mg/dl)	1.15±0.29	1.06±0.15	0.009
Glucose (mg/dl)	144.26±65.96	103.85±17.50	< 0.001
Na ⁺ (mEq/l)	140.97±1.60	140.88±1.58	0.729
K ⁺ (mEq/l)	4.17±0.34	4.24±0.32	0.194
Cholesterol (mg/dl)	182.92±37.44	165.35±22.59	< 0.001
TG (mg/dl)	183.70±50.43	160.22±36.02	0.001
HDL (mg/dl)	39.17±8.39	39.51±9.36	0.811
AST	24.81±27.39	25.70±21.37	0.820
ALT	22.86±14.68	30.86±25.94	0.018
ALP	214.36±51.52	200.83±51.68	0.099
LDL	94.26±40.13	98.53±38.12	0.491
TSH	3.69±11.64	2.60±9.09	0.511
FT4	1.80±1.78	2.02±1.90	0.443

cTnI = cardiac troponin I, CKMB = Creatine Kinase-MB isozyme, Na⁺ = sodium, K⁺ = potassium, TG = Triglyceride, HDL = high density lipoprotein, AST = aspartate transaminase, ALT = alanine transaminase, ALP = alkaline phosphatase, LDL = low-density lipoprotein, TSH = Thyroid-stimulating hormone, FT4 = free thyroxine

of presented graphs. Sample size was big enough to accept normal distribution of study groups, but we performed a Kolmogorov–Smirnov normality test (K-S test) for confirmation. Two-tailed $p < 0.005$ was considered statistically as significant. Correlation between miR-4478 expression and sLEPR was estimated using Pearson correlation coefficient. To determine the sensitivity and specificity of changes in miR-4478 expression as a discriminative predictor of NSTEMI disease, a Receiver Operating Characteristic (ROC) curve analysis was employed.

Results

Subject characteristics

Characteristics and some routine analyses of NSTEMI patients and healthy controls included in the current study are presented briefly in Table 1. Other tests that have been done in some of the included individuals were T3, T3up, HbA1c, Albumin, Amylase, CPK, Iron, TIBC, Uric acid, and VLDL, but their sample sizes were below 10 for patients and/or controls and then, analytical statistics were not done in them. No significant differences were observed in age, sex, BMI, and serum chemistries like sodium, potassium, HDL, AST, LDL, TSH, and FT4 levels. Nevertheless, patients with NSTEMI had higher serum concentrations of miR-4478 (shown by DeltaCqs), sLEPR, cTnI, CKMB, Urea, creatinine, glucose, cholesterol, TG, and ALP but lower levels of ALT compared with the normal healthy individuals.

Gene expression pattern of miR-4478 in NSTEMI patients and normal healthy individuals

Analyses of serum miR-4478 expressions were done by qPCR in all studied cases. Quality control analysis was done three




Fig. 1. Logarithm of input amount of serial dilutions of total RNA against their corresponding ΔCq s. R^2 = Coefficients of Determination.

times for each of 7 serial dilutions of stock cDNA solutions as follows: 1, 0.5, 0.2, 0.1, 0.05, 0.02, and 0.01. Results of regression analysis on logarithm of these dilutions and their corresponding ΔCq s plotted in Figure 1, show trustworthy of the qPCR analysis. Comparison of the mean values of $\Delta Cq.E$ and $\Delta Cq.C$ as well as $2^{-\Delta Cq.E}$ and $2^{-\Delta Cq.C}$ along with calculation of $2^{-\Delta \Delta Cq}$ (Fold Change in Gene Expression) indicated statistically lower expression of miR-4478 in the NSTEMI group compared with healthy group (Figs 2 and 3).

Serum level of sLEPR in NSTEMI patients and normal healthy group

ELISA analyses results showed a significant increase in sLEPR levels of NSTEMI patients (30.568 ± 3.290 ng/dl) compared with normal healthy individuals (23.740 ± 5.457 ng/dl) ($F = 3.645$, $p < 0.001$).

The predictive value of serum miR-4478 and sLEPR for NSTEMI

Receiver operating characteristic curves (ROC curves) were used to measure the sensitivity and specificity of the test as well as to predict the efficiency for NSTEMI disease, and the area under the ROC curve (AUC) was used to measure accuracy of the test. Correlation test (Pearson's) and linear regression test were also done.

Correlation test (Pearson's) showed correlation of -0.835 between $2^{-\Delta \Delta Cq}$ (Fold Change in Gene Expression) and sLEPR level ($p < 0.001$). Linear regression test showed $R^2 = 0.698$ with model equation of $LEPR = 32.658 - 13.00 \times 2^{-\Delta \Delta Cq}$ (Fig. 4).

The ROC curve analyses for $2^{-\Delta Cq}$ showed high sensitivity (87.5 %) and specificity (98.8 %) with $AUC = 0.936$ and accuracy = 0.931 (95 % confidence interval on the difference between the AUC and 0.5 (Two-tailed test) was 0.395–0.476, p -value (Two-tailed) < 0.0001) (Fig. 5).

The ROC curve analyses for sLEPR also showed high sensitivity (92.5 %) and specificity (87.5 %). AUC was equal to 0.862 and accuracy was equal to 0.900 (95 % confidence interval was 0.295–0.430, p -value (Two-tailed) < 0.0001) (Fig. 5).





Fig. 2. Mean \pm SD for $\Delta Cq.E$ and $\Delta Cq.C$ ($p < 0.0001$). $\Delta Cq.E$ = Difference between mean Cqs of experimental and housekeeping gene for patients, $\Delta Cq.C$ = Difference between mean Cqs of experimental and housekeeping gene for healthy controls, SD = Standard Deviation.





Fig. 3. Differences between Mean \pm SD levels by comparison of $2^{-\Delta \Delta Cq.E}$ and $2^{-\Delta \Delta Cq.C}$ ($p < 0.0001$). $2^{-\Delta \Delta Cq.E} = 2^{\text{power by minus } \Delta Cq.E}$, $2^{-\Delta \Delta Cq.C} = 2^{\text{power by minus } \Delta Cq.C}$, SD = Standard Deviation.




Fig. 4. Fig. 4. sLEPR levels of NSTEMI patients compared with normal healthy individuals ($F= 3.645, p< 0.0001$).




Fig. 5. Correlation and linear regression of $2^{-\Delta\Delta Cq}$ against soluble LEPR. $2^{-\Delta\Delta Cq} = 2$ power by minus difference between $\Delta Cq.E$ and $\Delta Cq.C$, LEPR = Leptin Receptor, Conf. interval = Confidence Interval, Obs = Observed, R^2 = Coefficients of Determination.

Correlations between miR-4478 and sLEPR and other variables

Correlation and linear regression of $2^{-\Delta\Delta Cq}$ as indicant of miR-4478 gene expression level against soluble LEPR is shown in Figure 6 ($p < 0.001, R^2 = 0.698$). Correlation and linear regression between $2^{-\Delta\Delta Cq}$ and sLEPR with other chemistries that have significant variation between patient and control groups (CKMB, Urea, Creatinine, Glucose, Na⁺, K⁺, Cholesterol, TG, HDL, and AST) were statistically compared. As shown in Table 3, there is statistically significant reverse correlation between fold change in expression of miR-4478 and serum concentrations of CKMB, and glucose. Similarly, there is a significant positive correlation between sLEPR and cTnI, CKMB, urea, glucose and cholesterol, and reverse correlation with ALT.

Discussion

Coronary artery diseases (CADs) are the most common and serious class of cardiovascular diseases (CVDs). Among CADs,

Tab. 2. Statistical results of independent t-test for changes in expression of miR-4478 in NSTEMI patients in comparison with control healthy group.

	No.	Mean±Standard Deviation (SD)	Description
TE.Cq - HE.Cq ($\Delta Cq.E$)	80	2.250±1.623	p (Two-tailed) < 0.0001
TC.Cq - HC.Cq ($\Delta Cq.C$)	80	-1.531±1.891	
$2^{-\Delta Cq.E}$	80	0.356±0.489	p (Two-tailed) < 0.0001
$2^{-\Delta Cq.C}$	80	5.669±7.505	
$2^{-\Delta\Delta Cq}$ (fold change)	80	0.161±0.211	Fold change is below basement (1)
$\log 2^{-\Delta\Delta Cq}$	80	-1.138±0.569	Log of fold change is below log of basement (0)

$\Delta Cq.E$ = Difference between mean Cqs of experimental and housekeeping gene for patients, $\Delta Cq.C$ = Difference between mean Cqs of experimental and housekeeping gene for healthy controls, $2^{-\Delta Cq.E}$ = 2 power by minus $\Delta Cq.E$, $2^{-\Delta Cq.C}$ = 2 power by minus $\Delta Cq.C$, $2^{-\Delta\Delta Cq}$ = 2 power by minus difference between $\Delta Cq.E$ and $\Delta Cq.C$, $\log 2^{-\Delta\Delta Cq}$ = logarithm of $2^{-\Delta\Delta Cq}$, SD = Standard Deviation

Tab. 3. Correlation of sLEPR and expression fold change in miR-4478 with some variables that were statistically different between patient and control groups. Numbers in bold represent significant correlation.

	p	Pearson's r	R ²
$2^{-\Delta Cq}$ cTnI	0.160	-0.112	0.012
$2^{-\Delta Cq}$ CKMB	0.004	-0.224	0.050
$2^{-\Delta Cq}$ Urea	0.088	-0.135	0.018
$2^{-\Delta Cq}$ Creatinine	0.157	-0.112	0.013
$2^{-\Delta Cq}$ Glucose	0.033	-0.169	0.029
$2^{-\Delta Cq}$ Cholesterol	0.283	-0.085	0.007
$2^{-\Delta Cq}$ TG	0.087	-0.136	0.018
$2^{-\Delta Cq}$ ALT	0.063	0.147	0.022
sLEPR cTnI	0.009	0.206	0.04
sLEPR CKMB	0.041	0.162	0.026
sLEPR Urea	0.005	0.221	0.049
sLEPR Creatinine	0.127	0.121	0.015
sLEPR Glucose	0.001	0.265	0.070
sLEPR Cholesterol	0.034	0.168	0.028
sLEPR TG	0.056	0.151	0.023
sLEPR ALT	0.007	-0.213	0.045

Pearson's r = Pearson's Regression, R² = Coefficients of Determination

myocardial infarction (MI, heart attack) has the highest rate of morbidity and mortality. NSTEMI (non-ST elevation myocardial infarction) is a type of MI that causes partial occlusion of infarct-




Fig. 6. The ROC curve for predicting NSTEMI. qPCR and ELISA assays was done for 80 NSTEMI patients and 80 normal controls to obtain $2^{-\Delta\Delta Cq}$ of miR-4478 and sLEPR values, respectively. a) The ROC curve for serum miR-4478 (sensitivity = 87.5 %, specificity = 98.8 %, AUC = 0.936, accuracy = 0.931, 95 % CI 0.395–0.476, $p < 0.0001$). b) The ROC curve for sLEPR (sensitivity = 92.5 %, specificity = 87.5 %, AUC = 0.862, accuracy = 0.900, 95 % CI 0.295–0.430, $p < 0.0001$). AUC = Area Under Curve.

ed artery. The importance of well-timed and proper recognition and management of NSTEMI is in that the partial occlusion in NSTEMI could be settled as a basement to subsequent accumulation of more substances that leads to complete occlusion of cardiac vessels and serious heart attack. Various biomarkers are used as diagnostic tools for cardiovascular diseases including NSTEMI, among them are cardiac troponins (I and T) and creatine Kinase-Muscle, Brain (CKMB). As an almost new branch of molecular biology, microRNAs brought about new strategies to quick and reliable diagnosis of various disorders, including heart diseases (27, 28), as their dysregulation has been found in many CVDs (29). Because of their very small sizes, microRNAs can easily cross cell membranes and appear in blood. So decrease or increase in their basal concentration in any given tissue would be reflected quickly in circulation and could be measured easily by bio molecular methods. So any pathologic status that causes changes in basal metabolism of the tissue would trigger variation in circulatory microRNA levels, much earlier than protein levels. So changes in circulatory concentration of any given microRNA could reflect metabolic alterations in the tissue that it comes from.

Human microRNA-4478 (hsa-mir-4478, miR-4478) was introduced in 2010 after sequencing of the small RNA transcriptome of normal and malignant human B cells that led to identification of hundreds of novel microRNAs (30). miR-4478 is encoded in chromosomal location of 9q33.2. Its mature form has 17 nucleotides with this sequence: 5'-gaggcugagcugaggag-3'. Soluble LEPR (sLEPR, sOB-R) resulting from cleavage of the extracellular domain of the transmembraneous leptin receptor can be present in dimeric or oligomerized states (13). sLEPR binds to leptin in ratio of 1 : 1 and modulates its biochemical action (14). Previous studies showed an increase in sLEPR levels in CVD patients (15) and miR-4478 has the highest target score (= 90) for LEPR (20). So we decided to test probable diminishment in miR-4478 expression as one of the reasons of increase in LEPR expression

and proposee this diminishment as a new biomarker for predicting NSTEMI. So the objectives of this study were:

- (a) Evaluating differences in circulatory miR-4478 levels in NSTEMI patients and healthy controls
- (b) Confirming sLEPR increase in NSTEMI patients in comparison with healthy controls,
- (c) Calculating the effects of changes in miR-4478 on sLEPR level, and
- (d) Investigating the role of miR-4478 as a new biomarker for prediction of NSTEMI.

In the present study, we showed that: (a) Circulatory concentration of miR-4478 was significantly lower ($\log 2^{-\Delta\Delta Cq} = -1.138 \pm 0.569$) but (b) sLEPR levels were statistically higher in NSTEMI patients (30.568 ± 3.290 ng/dl) than in the control group (23.740 ± 5.457 ng/dl) ($F = 3.645$, $p < 0.001$). (c) Statistically significant increases were in cTnI (0.001), CKMB (< 0.001), Urea (< 0.001), Creatinine (0.009), Glucose (< 0.001), Cholesterol (< 0.001), Triglyceride (0.001), levels and decrease was in ALT level (0.018). (d) There was a correlation between $2^{-\Delta\Delta Cq}$ (Fold Change in Gene Expression) and sLEPR level ($p < 0.001$, $r = -0.835$, $R^2 = 0.698$, sensitivity = 87.5 %, specificity = 98.8 %). (e) Both $2^{-\Delta\Delta Cq}$ (fold change in gene expression of microRNA-4478) and sLEPR levels had high sensitivity and specificity for prediction of NSTEMI disease (sensitivity = 87.5 % and specificity = 98.8 % with ROC curve AUC = 0.936 for fold change in gene expression, and sensitivity = 92.5 % and specificity = 87.5 % with ROC curve AUC = 0.862 for sLEPR level). (f) There was a significant reverse correlation between serum miR-4478 concentration and circulatory levels of CKMB, and glucose. (g) There was statistically positive correlation between sLEPR and cTnI, CKMB, urea, glucose and cholesterol, and reverse correlation with ALT.

The results and statistical interpretations of our study showed for the first time that there is a decrease in circulatory miR-4478 level that is in correlation with probable subsequent increase in sLEPR concentration. Circulatory miR-4478 and leptin receptor

levels are in correlation with some biofactors that are changed in NSTEMI disease, including cardiac troponin I, CKMB, cholesterol, and ALT. As LEPR and these biofactors are all important for the pathophysiology of NSTEMI as a cardiac disease, so increase in sLEPR and decrease in circulatory miR-4478 concentrations could be proposed a new biomarker for NSTEMI disease. Further studies may confirm our results by measuring intra-hepatocellular changes in miR-4478 and LEPR expression and proving these correlations.

References

- 1. Mortality GBD, Causes of Death C.** Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; 385 (9963): 117–171.
- 2. Mendis S, Puska P, Norrving B.** Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization, 2011.
- 3. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN et al.** Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. *Arch Iran Med* 2013; 16 (3): 138–144.
- 4. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al.** Executive summary: heart disease and stroke statistics – 2012 update: a report from the American Heart Association. *Circulation* 2012; 125 (1): 188–197.
- 5. Mehta PK, Wei J, Wenger NK.** Ischemic heart disease in women: a focus on risk factors. *Trends Cardiovasc Med* 2015; 25 (2): 140–151.
- 6. Castelli WP.** Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. *Can J Cardiol* 1988; 4 Suppl A: 5A–10A.
- 7. Adams JE, 3rd, Schechtman KB, Landt Y, Ladenson JH, Jaffe AS.** Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. *Clin Chem* 1994; 40 (7 Pt 1): 1291–1295.
- 8. Moe KT, Wong P.** Current trends in diagnostic biomarkers of acute coronary syndrome. *Ann Acad Med Singapore* 2010; 39 (3): 210–215.
- 9. Deckers JW.** Classification of myocardial infarction and unstable angina: a re-assessment. *Int J Cardiol* 2013; 167 (6): 2387–2390.
- 10. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M et al.** It's time for a change to a troponin standard. *Circulation* 2000; 102 (11): 1216–1220.
- 11. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R et al.** Identification and expression cloning of a leptin receptor, OB-R. *Cell* 1995; 83 (7): 1263–1271.
- 12. Tartaglia LA.** The leptin receptor. *J Biol Chem* 1997; 272 (10): 6093–6096.
- 13. Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J.** Soluble leptin receptor represents the main leptin binding activity in human blood. *Biochem Biophys Res Commun* 2001; 283 (4): 982–988.
- 14. Devos R, Guisez Y, Van der Heyden J, White DW, Kalai M, Fountoulakis M et al.** Ligand-independent dimerization of the extracellular domain of the leptin receptor and determination of the stoichiometry of leptin binding. *J Biol Chem* 1997; 272 (29): 18304–118305.
- 15. Schulze PC, Kratzsch J, Linke A, Schoene N, Adams V, Gielen S et al.** Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. *Eur J Heart Fail* 2003; 5 (1): 33–40.
- 16. Bartel DP.** MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; 116 (2): 281–297.
- 17. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R.** Control of translation and mRNA degradation by miRNAs and siRNAs. *Genes Dev* 2006; 20 (5): 515–524.
- 18. Hwang HW, Mendell JT.** MicroRNAs in cell proliferation, cell death, and tumorigenesis. *Br J Cancer* 2006; 94 (6): 776–780.
- 19. McCarthy JJ.** The MyomiR network in skeletal muscle plasticity. *Exerc Sport Sci Rev* 2011; 39 (3): 150–154.
- 20. Wang X.** miRDB: a microRNA target prediction and functional annotation database with a wiki interface. *RNA* 2008; 14 (6): 1012–1017.
- 21. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al.** The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem* 2009; 55 (4): 611–622.
- 22. Livak KJ, Schmittgen TD.** Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C (T)) Method. *Methods* 2001; 25 (4): 402–408.
- 23. van Iterson M, t Hoen PA, Pedotti P, Hooiveld GJ, den Dunnen JT, van Ommen GJ et al.** Relative power and sample size analysis on gene expression profiling data. *BMC Genomics* 2009; 10: 439.
- 24. Vaes E, Khan M, Mombaerts P.** Statistical analysis of differential gene expression relative to a fold change threshold on NanoString data of mouse odorant receptor genes. *BMC Bioinformatics* 2014; 15: 39.
- 25. Ramakers C, Ruijter JM, Deprez RH, Moorman AF.** Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. *Neurosci Lett* 2003; 339 (1): 62–66.
- 26. Academic Medical Center (AMC) in Amsterdam tN.** <http://www.hartfaalcentrum.nl/index.php?main=files&sub=LinRegPCR>.
- 27. Santovito D, Mezzetti A, Cipollone F.** MicroRNAs and atherosclerosis: new actors for an old movie. *Nutr Metab Cardiovasc Dis* 2012; 22 (11): 937–943.
- 28. Small EM, Frost RJ, Olson EN.** MicroRNAs add a new dimension to cardiovascular disease. *Circulation* 2010; 121 (8): 1022–1032.
- 29. Elzenaar I, Pinto YM, van Oort RJ.** MicroRNAs in heart failure: new targets in disease management. *Clin Pharmacol Ther* 2013; 94 (4): 480–489.
- 30. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW et al.** Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. *Blood* 2010; 116 (23): e118–127.

Received July 10, 2017.

Accepted August 18, 2017.